SOUTH SAN FRANCISCO, Calif., Oct. 23, 2007 (PRIME NEWSWIRE) -- Hana Biosciences (NasdaqGM:HNAB - News), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced the presentation of clinical data for Alocrest(tm) (vinorelbine tartrate injection, OPTISOME(tm)) at the ``Molecular Targets and Cancer Therapeutics’’ International Conference sponsored by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organization for Research and Treatment of Cancer (EORTC).
